Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Bone Marrow Transplant • Lymphoma • Myeloma • Internal Medicine • Hematology
How do you manage patients who develop de novo or recurrent skin cancers (SCC or BCC) while on lenalidomide?
Do these events mandate discontinuation of lenalidomide therapy or switching to a different agent? Can appropriate therapy for these skin cancers be rendered as needed while continuing the drug?
Does your choice above differ based on the indication for lenalidomide therapy (eg maintenance post-transplant vs front line therapy)?
SCC and BCC are the most common skin cancers. It w...